概述

恢复期血浆疗法利用已从疾病中康复的患者的血液来帮助其他患者恢复健康。

美国食品药品管理局(FDA)已紧急授权高抗体水平的恢复期血浆疗法用于治疗 COVID-19。处于疾病早期或免疫系统减弱的某些 COVID-19 住院患者可能会使用这种疗法。

COVID-19 康复患者捐献的血液中含有对抗致病病毒的抗体。捐献的血液经过处理,去除血细胞,留下液体部分(血浆)和抗体。将这些物质输注给 COVID-19 患者,可以增强他们抵抗病毒的能力。

目的

住院、处于疾病早期或免疫系统低下的 COVID-19 患者可接受恢复期血浆疗法。

恢复期血浆疗法可以帮助 2019 冠状病毒病患者康复。这种疗法可以减轻疾病的严重程度或缩短疾病的持续时间。

风险

血液已被用于治疗许多其他疾病。通常是十分安全的。从康复期患者的血浆中发现 2019 冠状病毒病 的风险还没有得到验证。但研究人员认为,出现该情况的风险很低,因为供体已经完全从感染中康复。

康复者血浆治疗有一定的风险,比如:

  • 过敏反应
  • 肺部损伤和呼吸困难
  • 感染HIV、乙型肝炎和丙型肝炎

这类感染出现的风险较低。捐献的血液必须进行安全性检测。一些人可能会出现轻微的并发症或完全没有并发症。其他一些人可能会出现严重甚至威胁生命的并发症。

可能出现的情况

如果您因患 COVID-19 而入院,且处于疾病早期或免疫系统低下,医生可能会考虑采取恢复期血浆治疗。如果对恢复期血浆治疗有疑问,请咨询医生。

医生将从医院的当地血液供应商处订购与血型相匹配的恢复期血浆。

术前

在进行恢复血浆疗法之前,您的医护团队将为您做好手术准备。医疗小组的一名成员会将一根无菌的一次性针头(静脉注射、IV 或输液管)插到您一只手臂的静脉中。

术中

血浆到达后,医生会将无菌血浆袋与导管相连,让血浆从无菌血浆袋中滴入导管。此程序大约需要 1 至 2 小时。

术后

医生会在您接受恢复期血浆后,对您进行密切监测。医生会记录您的治疗反应。还可能记录您需要住院多长时间以及是否需要其他治疗。

结果

目前尚不清楚恢复期血浆是否能有效治疗 COVID-19。您可能不会得到任何好处。但是,这种疗法可能有助于您从疾病中恢复。

多项临床试验、研究和一个全国护理使用项目的数据表明,高抗体水平的恢复期血浆可减轻处于疾病早期或免疫系统低下的 COVID-19 患者的病情或缩短其病程。但仍需要更多的研究来确定恢复期血浆疗法是否是治疗 COVID-19 的有效方法。

在 Mayo Clinic 治疗

April 28, 2021
  1. Convalescent plasma COVID-19: EUA letter of authorization. U.S. Food and Drug Administration. https://www.fda.gov/media/141477/download. Accessed April 22, 2021.
  2. Joyner MJ, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three month experience. Preprint. medRxiv. 2020; doi:10.1101/2020.08.12.20169359.
  3. FDA issues emergency use authorization for convalescent plasma as potential promising COVID–19 treatment. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed Aug. 24, 2020.
  4. Host modifiers and immune-based therapy under evaluation for treatment of COVID-19. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/. Accessed May 8, 2020.
  5. Donate COVID-19 plasma. U.S. Food and Drug Administration. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma. Accessed Aug. 24, 2020.
  6. Plasma donations from recovered COVID-19 patients. American Red Cross. https://www.redcrossblood.org/donate-blood/dlp/plasma-donations-from-recovered-covid-19-patients.html. Accessed May 8, 2020.
  7. Rajendran K, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology. 2020; doi:10.1002/jmv.25961.
  8. Investigational COVID-19 convalescent plasma — Emergency INDs: Frequently asked questions. U.S. Food and Drug Administration. https://www.fda.gov/media/136470/download. Accessed May 8, 2020.
  9. Expanded access to convalescent plasma for the treatment of patients with COVID-19. https://www.uscovidplasma.org/. Accessed Aug. 24, 2020.
  10. Coronavirus disease 2019 (COVID-2019). Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed May 8, 2020.
  11. Kim AR. Coronavirus disease 2019 (COVID-19): Management in hospitalized adults. https://www.uptodate.com/contents/search. Accessed May 8, 2020.
  12. AskMayoExpert. COVID-19: Adult. Mayo Clinic; 2020.
  13. Joyner MJ (expert opinion). Mayo Clinic. May 8, 2020.
  14. Emergency use authorization. U.S. Food and Drug Administration. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. . Accessed April 22, 2021.
  15. Coronavirus disease 2019 (COVID-19) treatment guidelines: Convalescent plasma. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/convalescent-plasma/. Accessed April 22, 2021.
  16. Klassen SA, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: Systematic review and meta-analysis. Mayo Clinic Proceedings. 2021; doi:10.1016/j.mayocp.2021.02.008.
  17. Joyner MJ, et al. Convalescent plasma antibody levels and risk of death from COVID-19. The New England Journal of Medicine. 2021; doi:10.1056/NEJMoa2031893.